Dr. Bhushan Dharmadhikari, PhD
Scientific Director ADC Discovery Other Target Classes, Monoclonal Antibodies, Multi-specific Antibodies, ADC, CAR-T & Other CGT, Cellular Assay, In Vivo Pharmacology, Oncology, Immunology, Autoimmune Disease
Dr. Bhushan Dharmadhikari is an expert in preclinical drug development, specializing in the preclinical pharmacology of therapeutic antibodies and Antibody-Drug Conjugates (ADCs) from early-stage discovery through Investigational New Drug (IND) submissions. He joined WuXi Biology in 2026, bringing over 12 years of biotechnology industry experience spanning immunology, oncology, and both in vitro and in vivo pharmacology. Before his current role, Dr. Dharmadhikari served as Senior Director and Head of Target Biology & Pharmacology at Hummingbird Bioscience (Singapore), where he spearheaded preclinical development and IND-enabling studies for multiple therapeutic assets, including dual-payload ADCs. He holds a PhD in Immunology from the National University of Singapore (NUS) and a postgraduate diploma in Management from Nanyang Business School (NTU).